OPIOID DEPENDENCY DETOX
new procedure for opioids use disorder

S.T. GENESIS


An FDA-cleared device that reduces the physical and emotional strain of withdrawal experienced by those suffering from opioid use disorder.


Dr. Michelle Weiner is providing patients with opioid dependency a non-invasive, direct route to get back to their life before opioids.

S.T. Genesis is an FDA-cleared Percutaneous Nerve Field Stimulator (PNFS) that supports a patient’s reduction of opioid withdrawal symptoms. Stimulation is performed by sending electrical pulses emitted through needles strategically positioned in the ear to branches of cranial nerves V, VII, IX, and X as well as the occipital nerves.

It is time to break free from the cycle of opioid dependency and regain your life!

S.T. Genesis / FDA-cleared Percutaneous Nerve Field Stimulator (PNFS)

Clinical data shows that nearly all adult patients included in the study successfully transitioned from the use of the device during detoxification (medically supervised opioid withdrawal) to medication assisted therapy (MAT). A reduction in Clinical Opioid Withdrawal Scale (COWS) scores was noticeable within 20 minutes of device placement, with scores continuing to drop over the five-day duration of opioid withdrawal treatment. This effective approach has been shown to allow patients to progress with recovery with the support of physician follow-up along with MAT.*

*Adrian Miranda & Arturo Taca (2018), The American Journal of Drug and Alcohol Abuse, 44:1, 56-63.

Frequently Asked Questions

About Opioid Dependency Detoxing

Patients with visible withdrawal symptoms (such as sweating, increased pulse rate, dilated pupils, nausea, vomiting) and those who measure with mild to severe withdrawal symptoms on the Clinical Opiate Withdrawal Scale (COWS) score. 

S.T. Genesis is an FDA-cleared Percutaneous Nerve Field Stimulator (PNFS) that supports a patient’s reduction of opioid withdrawal symptoms. Stimulation is performed by sending electrical pulses emitted through needles strategically positioned in the ear to branches of cranial nerves V, VII, IX, and X as well as the occipital nerves.

Speranza, the manufacturer of S.T. Genesis Treatment understands the difficulties in navigating the pathways to insurance reimbursement within the neuromodulation industry. That’s why they have created a separate division called Reimbursement Support Services. This division has been built with the patient and provider in mind to create seamless options to reimbursement and to ease the burden of obtaining proper reimbursement for the neuromodulation patient.

For assistance with the program forms or referral submission, please contact Speranza Support at 1-866-923-0710.

Education & ARTiCLES

Neuromodulation: Emerging Innovation and Greater Adoption

Neuromodulation works by actively stimulating nerves to produce a natural biological response. It is the alteration—or modulation—of nerve activity by delivering electrical stimulation directly to a targeted area of the central nervous system.1 Neuromodulation devices may be invasive or noninvasive.

Read More

A New Wave in the Opioid Epidemic – The Rise of Fentanyl Laced Drugs

In recent years, there has been an extreme rise in illicitly produced fentanyl being mixed into other drugs such as cocaine, counterfeit prescription pills, and methamphetamines. This, coupled with the increase in drug use and isolation from the pandemic, has ...

Read More

ST-Genesis-The-First-Step-In-The-OUD-Patients-Continuum-Of-Care-1024x536-1

S.T. Genesis: The First Step in the OUD Patient’s Continuum of Care

As the opioid use disorder (OUD) patient begins the journey to recovery, creating the best and most effective continuum of care can be a matter of life or death. Relapse rates in OUD patients post-detoxification are higher than any other drug, with 88% relapsing after 12 to 36 months.

Read More

In-Network Insurances Accepted

First consultation covered by insurance

(all others accepted Out-of-Network)
— list updated often —

Virtual Reality Effects on Pain Perception: Implications for Pain Management

Current Status: Pending

Literature suggests that the use of virtual reality distraction for adjunctive pain control has been successful. In clinical settings and experimental studies, participants immersed in a virtual reality experienced reduced levels of pain, general distress/unpleasantness and reported a desire to use virtual reality again during painful medical procedures.

There has been research into the use of virtual reality distraction for adjunctive pain control with significant success. There has been growing evidence for the use of EEG for the measurement of pain. It has also been suggested that virtual reality could be used an alternative to marijuana and opioids for pain management. Further implications have been seen specifically among chronic pain sufferers. This is especially interesting since there is a reduced risk of addiction as is seen associated with marijuana and opioid use. This study aims to investigate the effect of virtual reality distraction on pain perception.

Additionally, we intend to create a body of open source content for potential use by other investigators utilizing similar tools. 

The intervention has the potential to relieve chronic pain sufferers of their pain with a non-invasive mechanism and minimal risk. The participants may experience a temporary decrease in the perception of pain during the course of the experiment or a distraction from said pain.

Pending IRB approval at UM

Seniors Over 60 With Chronic Pain Using Medical Marijuana

Current Status: Active

 

The purpose of this study is to identify what is effective and safe for older adults with chronic pain to develop an understanding of what educational materials are required for facilitate access to appropriate products at medical marijuana treatment centers (MMTC). 

Survey older adults (> 50 years) with chronic pain who have MM access cards and receive their product from state-approved dispensaries to document: demographic/health data; patterns of use; product specifics; pain effects on daily life; pain-related medical conditions; education prior to MM purchase; helpful and problematic effects of MM use. 

The proportion of Florida’s population that is 60 and older is growing more rapidly than other components of the population. Musculoskeletal disorders with associated chronic pain are a common problem in later life. Symptom management in older adults, including chronic pain management can be challenging (Briscoe, 2018). Medications, especially opioids, can increase the risk of confusion, constipation, falls and injury (Briscoe,2018). Medical marijuana (MM) is often recommended by doctors in the treatment of these medical conditions, guided by state law that defines qualifying conditions.

Medical marijuana use among older adults is growing at a rate more rapid than younger age groups (Lum, et al, 2019). The 2016 National Survey on Drug Use and Health estimated a 2.9% prevalence of marijuana use among this older population. However, the survey did not ascertain if use was for medical or recreational purposes (Han et al., 2016). Older adults may have important differences in pathophysiology, pharmacological interaction of medications, comorbid conditions, and toxicological responses to cannabis.

There is little evidence to evaluate the differences associated with medical marijuana use among older adults, such as individual reasons for use and problems arising with use (Haug et al., 2017).

Chronic pain is a major public health problem. Approximately 178 million (41%) adults in the U.S. age 18 and older suffer from at least one painful health condition (Nahin, et al, 2019).

In Florida, there are 327,492 medical marijuana card holders and chronic non-malignant pain was the No. 1 diagnosis for which patients are registered (The Florida Department of Health, Office of Medical Marijuana Use, 2020). Yet, it is not a qualifying condition, creating challenges for physicians wishing to support patient use of MM for chronic pain.

Chronic pain accounted for nearly 34 percent of diagnoses at certified dispensaries (The Florida Department of Health, Office of Medical Marijuana Use, 2019).